Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers.

ABSTRACT: Precision oncology led to the establishment and widespread application of molecular tumor boards (MTBs)-multidisciplinary units combining molecular and clinical assessment of individual cancer cases for swift selection of personalized treatments. Whole-exome or gene panel sequencing, combined with transcriptomic, immunohistochemical, and other molecular analyses, often permits dissection of molecular drivers of a tumor and identification of its potential targetable vulnerabilities, instructing clinical oncologists on sometimes unconventional treatment options. However, cancer drivers are often unleashed mutation-independently, especially in breast and gynecological cancers, and deleterious mutations are not always pathogenic. To complement the MTB arsenal, we chart here the molecular tools

SUBMITTER: Denisenko TV 

PROVIDER: S-EPMC12322122 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature